Due to its promising effect, in 2012, PON was granted accelerated FDA approval for the treatment of CML patients with the BCR-ABL1 T315I mutation and for patients with CML resistant to two or more TKIs [10]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.